Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BIIB
BIOGEN INC.
NASDAQ
$218.50
▼ DOWN 1.35% (-3.00)

KEY STATISTICS

Market Cap$32.28 B
52w High$222.85
52w Low$133.53
Dividend Yield—
Frequency—
P/E13.79
Volume517.36K
Shares Out.147.75M

COMPANY

LEADERSHIP

Christopher A. Viehbacher
CHIEF EXECUTIVE
Christopher A. Viehbacher

COMPENSATION 2026

Salary$1,727,885
Stock Awards$18,368,875
Incentive Plan Pay$3,190,875
All Other Comp.$358,369
Total$23,646,004

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 17, 1991
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
7,500

PRICE TARGET

Target High$300.00
Target Low$157.00
Target Median$248.00
Target Consensus$243.60

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$2.64B
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2001-01-18Forward3:1
1999-12-21Forward2:1

PRICE

$218.50 ▼ DOWN 1.35% (−$3.00)
OVERLAYS
$218$219$2219:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM218.50

About Biogen Inc.

https://www.biogen.com ↗

Biogen Inc. develops therapies for neurological diseases, including multiple sclerosis, Alzheimer's, and neurodegenerative disorders, with a broad portfolio of biologics, biosimilars, and research collaborations.

INDUSTRY

Drug Manufacturers - General

A PRODUCT BIOGEN INC. IS KNOWN FOR

Leqembi (lecanemab)
Leqembi (lecanemab)

Leqembi, an FDA-approved antibody therapy for Alzheimer's that removes amyloid beta plaques, is a key growth driver for Biogen's focus on neurological diseases and represents the company's shift toward innovative treatments.

COMPETITORS

COMPETITOR
ABOS COMPARE
AVXL COMPARE
LLY COMPARE
PRTA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
MS Product Revenues$1.06B $917.2M ▼$957.5M ▲$963.3M ▲
TYSABRI product$431.8M $397.5M ▼$441.5M ▲$450.8M ▲
SPINRAZA$374M $356.2M ▼$374M ▲$401.9M ▲
Fumarate$382.8M $292.9M ▼$288.5M ▼$287.4M ▼
Interferon$246.9M $225.7M ▼$227.5M ▲$225.1M ▼

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$935.3M $0 ▼$839.2M ▲$1.11B ▲
NonUS$911.6M $749.6M ▼$913.1M ▲$801.9M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,002
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.04% · 4.7M
XWD.TO
0.04% · 2.0M
SPY
0.05% · 1.8M
SZNE
6.84% · 1.1M
RSP
0.21% · 969.4K
FBT
3.37% · 454.6K
GSLC
0.25% · 175.2K
SCHX
0.05% · 157.3K
XDEW.DE
0.21% · 157.2K
DFAC
0.05% · 114.9K
JAVA
0.33% · 103.9K
FHLC
0.44% · 70.5K
BBH
3.12% · 67.8K
HMWA.L
0.07% · 59.0K
JHMM
0.20% · 55.8K
XZ
XZME.F
0.12% · 50.5K
AVUS
0.08% · 49.5K
WSRUS.SW
0.14% · 46.5K
ZSP.TO
0.05% · 46.0K
PB
PBPH
0.71% · 33.5K
LEMA.L
0.06% · 32.3K
SPYI
0.05% · 25.9K
CLSE
0.54% · 22.1K
LABU
0.69% · 19.8K
TCAF
0.05% · 18.5K
FRTY
2.55% · 17.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.95%
HOLDERS
1,630
TOP 12 OF 1,630 · RANKED BY POSITION SIZE
Fmr LLC
18.2M sh · $3.94B
Vanguard Group Inc
17.4M sh · $3.07B
Blackrock, Inc.
16.0M sh · $3.45B
Primecap Management Co/Ca/
15.2M sh · $3.27B
Blackrock Inc.
14.5M sh · $3.37B
Icahn Capital LP
12.9M sh · $943.81K
State Street Corp
7.3M sh · $1.59B
Blackrock Institutional Trust Company, N.A.
6.1M sh · $1.73B
Blackrock Fund Advisors
5.3M sh · $1.5B
Geode Capital Management, LLC
4.4M sh · $957.94M
Wellington Management Group Llp
4.2M sh · $594.85M
Point72 Asset Management, L.P.
3.9M sh · $542.52M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity3
Return On Assets4
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-06-05
 Maria Elvira Salazar
Maria Elvira Salazar
Sale
2026-06-02
 Ro Khanna
Ro Khanna
Purchase
2025-08-26
 Rob Bresnahan
Rob Bresnahan
Purchase
2025-05-15

INSIDER TRADES

★
OFFICER
Parini Michael
— · —
2026-08-03
★
DIRECTOR
Minor Lloyd
Sale · 593 shares
2026-08-03
★
DIRECTOR
Minor Lloyd
Purchase · 1.5K shares
2026-06-09
★
DIRECTOR
Freire Maria C
Purchase · 2.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 8
OUTPERFORM 4
NEUTRAL 4
EQUAL WEIGHT 2
OVERWEIGHT 2
MARKET PERFORM 2
REDUCE 1
HOLD 1
24 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM Wolfe Research OUTPERFORM Mizuho OUTPERFORM Citigroup NEUTRAL TD Cowen BUY Canaccord Genuity BUY Morgan Stanley EQUAL WEIGHT UBS BUY

SECTORS PEERS

PEERPRICE
TEVA$36.44COMPARE
DXCM$90.82COMPARE
WAT$414.69COMPARE
LH$335.11COMPARE
DGX$242.76COMPARE
INCY$124.37COMPARE
STE$233.78COMPARE
UTHR$515.46COMPARE